Pub Date : 2026-02-07DOI: 10.1016/j.lana.2026.101387
Andre Luiz Oliveira da Silva , Stanton A. Glantz
{"title":"Reassessing Spinola et al.: data, sources, and the case for Brazil's e-cigarette ban","authors":"Andre Luiz Oliveira da Silva , Stanton A. Glantz","doi":"10.1016/j.lana.2026.101387","DOIUrl":"10.1016/j.lana.2026.101387","url":null,"abstract":"","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"56 ","pages":"Article 101387"},"PeriodicalIF":7.0,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146135697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.lana.2026.101378
Orison O. Woolcott
{"title":"The Latin American Diabetes Association 2025 congress","authors":"Orison O. Woolcott","doi":"10.1016/j.lana.2026.101378","DOIUrl":"10.1016/j.lana.2026.101378","url":null,"abstract":"","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"54 ","pages":"Article 101378"},"PeriodicalIF":7.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146077821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.lana.2026.101381
Klauss Villalva-Serra , Beatriz Barreto-Duarte , Moreno M. Rodrigues , Artur T.L. Queiroz , Leonardo Martinez , Julio Croda , Valeria C. Rolla , Afrânio L. Kritski , Marcelo Cordeiro-Santos , Timothy R. Sterling , Mariana Araújo-Pereir , Bruno B. Andrade
{"title":"Corrigendum to “Impact of strategic public health interventions to reduce tuberculosis incidence in Brazil: a Bayesian structural time-series scenario analysis” - The Lancet Regional Health – Americas 2025; Volume 41: 100963; DOI: 10.1016/j.lana.2024.100963","authors":"Klauss Villalva-Serra , Beatriz Barreto-Duarte , Moreno M. Rodrigues , Artur T.L. Queiroz , Leonardo Martinez , Julio Croda , Valeria C. Rolla , Afrânio L. Kritski , Marcelo Cordeiro-Santos , Timothy R. Sterling , Mariana Araújo-Pereir , Bruno B. Andrade","doi":"10.1016/j.lana.2026.101381","DOIUrl":"10.1016/j.lana.2026.101381","url":null,"abstract":"","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"54 ","pages":"Article 101381"},"PeriodicalIF":7.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146077820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-29DOI: 10.1016/j.lana.2026.101376
Benedikt Fischer , Wayne Hall , Bernard Le Foll , Patricia Conrod
{"title":"‘Strategic approaches to reducing the substance use-related burden of disease in Canada’ — authors' reply","authors":"Benedikt Fischer , Wayne Hall , Bernard Le Foll , Patricia Conrod","doi":"10.1016/j.lana.2026.101376","DOIUrl":"10.1016/j.lana.2026.101376","url":null,"abstract":"","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"55 ","pages":"Article 101376"},"PeriodicalIF":7.0,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146078147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-28DOI: 10.1016/j.lana.2026.101382
Laura Nicolaou , Carolyn J. Reuland , Mingling Yang , Kendra N. Williams , Stella M. Hartinger , Marilú Chiang , William Checkley
Background
Household air pollution (HAP) is a major global health risk. Observational studies link HAP exposure to impaired child growth, but randomized controlled trial (RCT) evidence is inconsistent.
Methods
We followed children born during an RCT of an 18-month liquefied petroleum gas (LPG) intervention among 800 pregnant women in Puno, Peru. We measured personal exposures to fine particulate matter (PM2.5) and carbon monoxide (CO) three times during pregnancy and three times during infancy. We measured length quarterly between birth and 12 months and height once between age 2–4 years. We assessed the effect of the LPG intervention on growth trajectories and evaluated exposure-response associations between height-for-age z-score (HAZ) and PM2.5 or CO exposures.
Findings
We revisited 683 children (mean age 34.0 ± 6.6 months, 49.3% male, 52.3% intervention). Mean HAZ at age 2–4 years was −0.92 ± 0.83 SDs in intervention children and −1.00 ± 0.80 SDs in controls (p = 0.33). In intention-to-treat analysis, the HAZ difference between groups was 0.08 SDs (95% CI −0.04 to 0.21) favoring the intervention. Neither prenatal nor postnatal PM2.5 or CO exposures were associated with HAZ. A 10 μg/m3 difference in prenatal and postnatal PM2.5 corresponded to a HAZ difference of −0.003 SDs (−0.011 to 0.005) and −0.001 SDs (−0.005 to 0.007), respectively. A 1 ppm difference in prenatal or postnatal CO corresponded to −0.009 SDs (−0.025 to 0.008) and 0.000 (−0.011 to 0.012), respectively.
Interpretation
Children of mothers randomized to LPG were not taller than controls. Personal PM2.5 or CO exposures did not influence child growth.
Funding
US National Institutes of Health; Bill & Melinda Gates Foundation.
{"title":"Long-term effects of cooking with liquefied petroleum gas or biomass on linear growth trajectories from birth to the pre-school years in Puno, Peru: a prospective cohort study","authors":"Laura Nicolaou , Carolyn J. Reuland , Mingling Yang , Kendra N. Williams , Stella M. Hartinger , Marilú Chiang , William Checkley","doi":"10.1016/j.lana.2026.101382","DOIUrl":"10.1016/j.lana.2026.101382","url":null,"abstract":"<div><h3>Background</h3><div>Household air pollution (HAP) is a major global health risk. Observational studies link HAP exposure to impaired child growth, but randomized controlled trial (RCT) evidence is inconsistent.</div></div><div><h3>Methods</h3><div>We followed children born during an RCT of an 18-month liquefied petroleum gas (LPG) intervention among 800 pregnant women in Puno, Peru. We measured personal exposures to fine particulate matter (PM<sub>2.5</sub>) and carbon monoxide (CO) three times during pregnancy and three times during infancy. We measured length quarterly between birth and 12 months and height once between age 2–4 years. We assessed the effect of the LPG intervention on growth trajectories and evaluated exposure-response associations between height-for-age z-score (HAZ) and PM<sub>2.5</sub> or CO exposures.</div></div><div><h3>Findings</h3><div>We revisited 683 children (mean age 34.0 ± 6.6 months, 49.3% male, 52.3% intervention). Mean HAZ at age 2–4 years was −0.92 ± 0.83 SDs in intervention children and −1.00 ± 0.80 SDs in controls (p = 0.33). In intention-to-treat analysis, the HAZ difference between groups was 0.08 SDs (95% CI −0.04 to 0.21) favoring the intervention. Neither prenatal nor postnatal PM<sub>2.5</sub> or CO exposures were associated with HAZ. A 10 μg/m<sup>3</sup> difference in prenatal and postnatal PM<sub>2.5</sub> corresponded to a HAZ difference of −0.003 SDs (−0.011 to 0.005) and −0.001 SDs (−0.005 to 0.007), respectively. A 1 ppm difference in prenatal or postnatal CO corresponded to −0.009 SDs (−0.025 to 0.008) and 0.000 (−0.011 to 0.012), respectively.</div></div><div><h3>Interpretation</h3><div>Children of mothers randomized to LPG were not taller than controls. Personal PM<sub>2.5</sub> or CO exposures did not influence child growth.</div></div><div><h3>Funding</h3><div><span>US National Institutes of Health</span>; <span>Bill & Melinda Gates Foundation</span>.</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"55 ","pages":"Article 101382"},"PeriodicalIF":7.0,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146078714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-28DOI: 10.1016/j.lana.2025.101371
Lucas Almeida Andrade , Maria Amélia dos Santos Lemos Gurgel , Wandklebson Silva da Paz , Glauber Rocha Monteiro , Karina Conceição Gomes de Araújo , Allan Dantas dos Santos , Carlos Dornels Freire de Souza , Álvaro Francisco Lopes de Sousa , Lariane Angel Cepas , Ana Paula Morais Fernandes , Débora dos Santos Tavares , Tatiana Rodrigues de Moura , Márcio Bezerra-Santos
Background
The COVID-19 pandemic has disrupted healthcare services and intensified socio-economic vulnerabilities, potentially escalating harmful substance use. In Brazil, pre-pandemic mortality from alcohol and drug use was stable. However, the pandemic introduced new risks that may have triggered a significant increase in related deaths. This study, therefore, aims to assess the impact of the COVID-19 pandemic on alcohol- and drug-related deaths in Brazil from 2020 to 2022.
Methods
This population-based ecological study analyzed alcohol- and drug-related mortality across Brazil from 2015 to 2022 using data from the Brazilian Mortality Information System (SIM). Temporal trends were examined using Joinpoint regression, while interrupted time-series analyses assessed deviations post-pandemic onset. Spatial variations were visualized using choropleth maps.
Findings
Alcohol- and drug-related mortality increased by 18.3% in 2020, 22.4% in 2021, and 26.0% in 2022. The Northeast (2020 = 24.9%; 2021 = 24.0%; 2022 = 31.8%), Southeast (2020 = 18.2%; 2021 = 24.3%; 2022 = 21.0%), and South (2020 = 13.1%; 2021 = 23.6%; 2022 = 35.2%) regions recorded the highest increases, with most states showing significant growth in deaths. We also observed an increase in mortality associated with the use of Psychoactive substances (PAS) in both sexes (male: average annual percentage changes (AAPCs) = 3.6%; female: AAPC = 4.6%), individuals aged 20 to 39 (AAPC = 2.0%), and those aged 60 and above (AAPC = 1.8%). Interrupted time-series analyses confirmed a marked and statistically significant increase in mortality post-March 2020.
Interpretation
The findings suggest a collateral epidemic of substance-related deaths fueled by the COVID-19 pandemic's disruptions to harm reduction services, treatment access, and socio-economic stability. These results underscore the urgent need to enhance healthcare systems, reinforce harm reduction services, and develop intersectoral policies targeting social inequalities to mitigate future crises.
Funding
This research is part of the PEGA@ACAO study and was funded by the São Paulo Research Foundation (FAPESP, grant #2024/15320-5 and #2025/04763-6); the National Council for Scientific and Technological Development (CNPq, grant #405741/2024-3); and the Coordination for the Improvement of Higher Education Personnel (CAPES, finance code #001).
{"title":"Alcohol- and drug-related mortality in Brazil: an ecological and population-based study on changes observed during the COVID-19 pandemic","authors":"Lucas Almeida Andrade , Maria Amélia dos Santos Lemos Gurgel , Wandklebson Silva da Paz , Glauber Rocha Monteiro , Karina Conceição Gomes de Araújo , Allan Dantas dos Santos , Carlos Dornels Freire de Souza , Álvaro Francisco Lopes de Sousa , Lariane Angel Cepas , Ana Paula Morais Fernandes , Débora dos Santos Tavares , Tatiana Rodrigues de Moura , Márcio Bezerra-Santos","doi":"10.1016/j.lana.2025.101371","DOIUrl":"10.1016/j.lana.2025.101371","url":null,"abstract":"<div><h3>Background</h3><div>The COVID-19 pandemic has disrupted healthcare services and intensified socio-economic vulnerabilities, potentially escalating harmful substance use. In Brazil, pre-pandemic mortality from alcohol and drug use was stable. However, the pandemic introduced new risks that may have triggered a significant increase in related deaths. This study, therefore, aims to assess the impact of the COVID-19 pandemic on alcohol- and drug-related deaths in Brazil from 2020 to 2022.</div></div><div><h3>Methods</h3><div>This population-based ecological study analyzed alcohol- and drug-related mortality across Brazil from 2015 to 2022 using data from the Brazilian Mortality Information System (SIM). Temporal trends were examined using Joinpoint regression, while interrupted time-series analyses assessed deviations post-pandemic onset. Spatial variations were visualized using choropleth maps.</div></div><div><h3>Findings</h3><div>Alcohol- and drug-related mortality increased by 18.3% in 2020, 22.4% in 2021, and 26.0% in 2022. The Northeast (2020 = 24.9%; 2021 = 24.0%; 2022 = 31.8%), Southeast (2020 = 18.2%; 2021 = 24.3%; 2022 = 21.0%), and South (2020 = 13.1%; 2021 = 23.6%; 2022 = 35.2%) regions recorded the highest increases, with most states showing significant growth in deaths. We also observed an increase in mortality associated with the use of Psychoactive substances (PAS) in both sexes (male: average annual percentage changes (AAPCs) = 3.6%; female: AAPC = 4.6%), individuals aged 20 to 39 (AAPC = 2.0%), and those aged 60 and above (AAPC = 1.8%). Interrupted time-series analyses confirmed a marked and statistically significant increase in mortality post-March 2020.</div></div><div><h3>Interpretation</h3><div>The findings suggest a collateral epidemic of substance-related deaths fueled by the COVID-19 pandemic's disruptions to harm reduction services, treatment access, and socio-economic stability. These results underscore the urgent need to enhance healthcare systems, reinforce harm reduction services, and develop intersectoral policies targeting social inequalities to mitigate future crises.</div></div><div><h3>Funding</h3><div>This research is part of the PEGA@ACAO study and was funded by the São Paulo Research Foundation (FAPESP, grant #2024/15320-5 and #2025/04763-6); the National Council for Scientific and Technological Development (CNPq, grant #405741/2024-3); and the Coordination for the Improvement of Higher Education Personnel (CAPES, finance code #001).</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"55 ","pages":"Article 101371"},"PeriodicalIF":7.0,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146078146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-19DOI: 10.1016/j.lana.2026.101373
Samantha Rundle , Maryam Iraniparast , David Hammond
Background
The bidirectional relationship between cannabis use and mental health is complex. With the liberalization of cannabis laws in many countries, it is increasingly important to understand the impacts of cannabis legalization on individuals with mental health conditions. This study aimed to examine changes in cannabis use by mental health status pre-versus 5-years post-legalization of recreational cannabis in Canada.
Methods
Data were from the International Cannabis Policy Study's national repeat cross-sectional surveys, conducted annually in Canada between 2018 and 2023, one year before and five years after the legalization of cannabis. The current analysis includes 92,843 Canadians aged 16–65 years. Adjusted logistic regression models examined changes in daily and past 12-month cannabis use pre-versus post-legalization among individuals experiencing each of the five mental health problems in the last year: anxiety, bipolar, depression, post-traumatic stress disorder (PTSD), and schizophrenia.
Findings
Past 12-month cannabis consumption increased from pre-legalization versus the year immediately following legalization (2019) among those with anxiety (adjusted odds ratio (AOR) = 1.33, 95% CI = 1.15, 1.53, p < 0.0001), depression (AOR = 1.47, 95% CI = 1.26, 1.73, p < 0.0001), and those reporting ‘no experience’ of a mental health problem in the past year (AOR = 1.52, 95% CI = 1.37, 1.68, p < 0.0001). Past 12-month cannabis use remained significantly higher in 2023 versus pre-legalization for anxiety and depression. Daily cannabis use increased from 2018 to 2019 only among those not reporting any experience of a mental health problem in the past year (AOR = 1.34, 95% CI = 1.10, 1.62, p < 0.0001). No other pre-post legalization differences were observed among individuals who experienced bipolar, PTSD, or schizophrenia.
Interpretation
Few changes in cannabis use were observed pre-versus post-cannabis legalization among Canadians who reported experiencing a mental health problem, whereas daily and past 12-month use increased among Canadians not reporting a mental health problem.
Funding
Funding for the ICPS study was provided by a Canadian Institutes of Health Research Project Grant and Project Bridge Grant (PJT-153342).
大麻使用与心理健康之间的双向关系是复杂的。随着许多国家大麻法律的放宽，了解大麻合法化对有精神健康问题的个人的影响变得越来越重要。本研究旨在研究加拿大娱乐性大麻合法化前与5年后大麻使用心理健康状况的变化。方法数据来自国际大麻政策研究的全国重复横断面调查，该调查于2018年至2023年在加拿大进行，分别是大麻合法化的前一年和后五年。目前的分析包括92,843名年龄在16-65岁之间的加拿大人。调整后的逻辑回归模型检查了去年经历五种精神健康问题（焦虑、双相情感障碍、抑郁、创伤后应激障碍和精神分裂症）的个体在大麻合法化前和合法化后每天和过去12个月大麻使用情况的变化。研究发现，与合法化后的一年（2019年）相比，过去12个月的大麻消费量在焦虑（调整优势比(AOR) = 1.33, 95% CI = 1.15, 1.53, p < 0.0001）、抑郁（AOR = 1.47, 95% CI = 1.26, 1.73, p < 0.0001）和报告在过去一年中“没有经历”精神健康问题的人（AOR = 1.52, 95% CI = 1.37, 1.68, p < 0.0001）中有所增加。与合法化前相比，2023年过去12个月的大麻使用量仍明显高于焦虑和抑郁。从2018年到2019年，只有在过去一年没有任何精神健康问题经历的人群中，每日大麻使用量有所增加（AOR = 1.34, 95% CI = 1.10, 1.62, p < 0.0001）。在经历过双相情感障碍、创伤后应激障碍或精神分裂症的个体中，没有观察到其他的合法化前后差异。解释在报告有精神健康问题的加拿大人中，大麻使用在大麻合法化之前和之后几乎没有变化，而在报告没有精神健康问题的加拿大人中，每天和过去12个月的大麻使用有所增加。ICPS研究的资金由加拿大卫生研究院项目资助和项目桥梁资助（PJT-153342）提供。
{"title":"The prevalence of cannabis use pre-versus post-cannabis legalization in Canada by mental health status: findings from national repeat cross-sectional surveys","authors":"Samantha Rundle , Maryam Iraniparast , David Hammond","doi":"10.1016/j.lana.2026.101373","DOIUrl":"10.1016/j.lana.2026.101373","url":null,"abstract":"<div><h3>Background</h3><div>The bidirectional relationship between cannabis use and mental health is complex. With the liberalization of cannabis laws in many countries, it is increasingly important to understand the impacts of cannabis legalization on individuals with mental health conditions. This study aimed to examine changes in cannabis use by mental health status pre-versus 5-years post-legalization of recreational cannabis in Canada.</div></div><div><h3>Methods</h3><div>Data were from the International Cannabis Policy Study's national repeat cross-sectional surveys, conducted annually in Canada between 2018 and 2023, one year before and five years after the legalization of cannabis. The current analysis includes 92,843 Canadians aged 16–65 years. Adjusted logistic regression models examined changes in daily and past 12-month cannabis use pre-versus post-legalization among individuals experiencing each of the five mental health problems in the last year: anxiety, bipolar, depression, post-traumatic stress disorder (PTSD), and schizophrenia.</div></div><div><h3>Findings</h3><div>Past 12-month cannabis consumption increased from pre-legalization versus the year immediately following legalization (2019) among those with anxiety (adjusted odds ratio (AOR) = 1.33, 95% CI = 1.15, 1.53, <em>p</em> < 0.0001), depression (AOR = 1.47, 95% CI = 1.26, 1.73, <em>p</em> < 0.0001), and those reporting ‘no experience’ of a mental health problem in the past year (AOR = 1.52, 95% CI = 1.37, 1.68, <em>p</em> < 0.0001). Past 12-month cannabis use remained significantly higher in 2023 versus pre-legalization for anxiety and depression. Daily cannabis use increased from 2018 to 2019 only among those not reporting any experience of a mental health problem in the past year (AOR = 1.34, 95% CI = 1.10, 1.62, <em>p</em> < 0.0001). No other pre-post legalization differences were observed among individuals who experienced bipolar, PTSD, or schizophrenia.</div></div><div><h3>Interpretation</h3><div>Few changes in cannabis use were observed pre-versus post-cannabis legalization among Canadians who reported experiencing a mental health problem, whereas daily and past 12-month use increased among Canadians not reporting a mental health problem.</div></div><div><h3>Funding</h3><div>Funding for the ICPS study was provided by a <span>Canadian Institutes of Health Research Project Grant and Project Bridge Grant</span> (PJT-153342).</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"55 ","pages":"Article 101373"},"PeriodicalIF":7.0,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146037678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-14DOI: 10.1016/j.lana.2026.101377
Taissa Vila, Orison O. Woolcott
{"title":"Advancing maternal and child health and nutrition in Ecuador: a call for research","authors":"Taissa Vila, Orison O. Woolcott","doi":"10.1016/j.lana.2026.101377","DOIUrl":"10.1016/j.lana.2026.101377","url":null,"abstract":"","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"54 ","pages":"Article 101377"},"PeriodicalIF":7.0,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145976914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号